Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hepatitis A virus strain, method for preparing hepatitis A inactivated vaccine and obtained vaccine

A hepatitis A virus and hepatitis A technology, applied in biochemical equipment and methods, virus/bacteriophage, and vector-borne diseases, can solve the problems of high manufacturing cost and low reproduction efficiency of hepatitis A inactivated vaccines, and achieve Guaranteed effectiveness, high virus yield, and reduced production costs

Inactive Publication Date: 2003-09-24
YUXI WALVAX BIOTECH CO LTD
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The cell substrates adapted to the hepatitis A virus strains of existing hepatitis A inactivated vaccines (including attenuated vaccines) are human diploid cells or human fibroblasts, and their common feature is that the reproduction efficiency is not high. Purified viral antigen, which is the root cause of the high cost of manufacturing inactivated hepatitis A vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0028] In the method for preparing the hepatitis A inactivated vaccine of the present invention, the cell matrix described in step (a) is Vero cell, and this cell can be purchased from ATCC, for example, and culture medium is the MEM that has serum culture medium such as containing 10% serum As for the culture medium, the culture temperature is well known to those skilled in the art, usually 36.5-37.5°C.

[0029] The culture medium in step (b) is a serum-containing culture medium such as MEM culture medium containing 2% serum, and the culture temperature is well known to those skilled in the art, usually 34.5-35.5°C, and no cytopathic pathology (CPE) occurs during the culture process.

[0030] The preparation of the vaccine from the purified virus in step (d) can be carried out using conventional methods in the art, for example, the following method can be used: first, the virus-cell culture suspension is ultrasonically crushed until the cell disruption rate reaches more than 9...

Embodiment 1

[0031] The present invention is described in more detail with examples below. Embodiment 1: the breeding method of hepatitis A virus strain YN5

[0032] (a) The virus was isolated from the feces of clinical hepatitis A patients, and tested by biological characteristics

[0033] Confirmed to be hepatitis A virus;

[0034] (b) Blind on diploid cell 2BS (source: China Institute for the Control of Pharmaceutical and Biological Products)

[0035] Adapted to 6 generations;

[0036] (c) Then cultivate and adapt to Vero for 40 days, and then gradually reduce the culture time until

[0037] To the peak of proliferation at 14 days.

[0038] Wherein, after each culture period expires, the virus-cell culture suspension is obtained by digestion with trypsin-EDTA, and stored at -60°C to -80°C for future use. Before inoculation, the cells were crushed by ultrasonic waves until the cell crushing rate reached over 95%. Vaccinations were performed at an infectious dose (M.O.I.) o...

Embodiment 2

[0039] Finally, a desired Hepatitis A virus strain with desired characteristics was obtained, named YN5, which was deposited in China Center for Type Culture Collection on April 20, 2001, with the preservation number CCTCC NO: V200104. Embodiment 2: the preparation of hepatitis A inactivated vaccine

[0040] Take out the Vero cell ampoule (source: National Institute for the Control of Pharmaceutical and Biological Products) from the liquid nitrogen container, centrifuge at 1000rpm for 10 minutes, discard the original preservation solution, add the MEM nutrient solution containing 10% neonatal bovine serum, 0.20% hydrolyzed milk protein (with 7% NaHCO 3 Adjust the pH to 6.8) and culture at 37°C. After the cells grow into a single layer, they are washed with PBS, digested with trypsin-EDTA, added to the above nutrient solution, and subcultured once every 5 days at a seeding rate of 1:2 until the cells are obtained. Sufficient cells for bulk production.

[0041] The above cells...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new hepatitis A virus strain YN5, and method for preparing hepatitis A inactivated vaccine by using said virus strain YB5 and Vero cell and the vaccine made up by using said method. Said invention also relates to the method for breeding said virus strain.

Description

technical field [0001] The invention relates to a novel hepatitis A virus strain, a method for preparing an inactivated hepatitis A vaccine by using it, and the vaccine prepared by the method. The invention particularly relates to a method for preparing an inactivated hepatitis A vaccine using Vero cells and the vaccine prepared by the method. The invention also relates to a breeding method for hepatitis A virus strains. Background technique [0002] Hepatitis A is an acute intestinal infectious disease caused by hepatitis A virus infecting the human body. Hepatitis A is one of the six viral hepatitis that has been found to seriously affect human health, and has the highest infection rate. my country is a high prevalence area of ​​hepatitis A, and there are epidemics or outbreaks every year. In the spring of 1988, a hepatitis A pandemic broke out in Shanghai, and nearly 300,000 people were infected, causing serious social impact and huge economic losses. There is no effe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/29C12N7/01C12N7/04
CPCY02A50/30
Inventor 陈尔佳
Owner YUXI WALVAX BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com